Loading...
Loading...
ATHA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 200.0K |
| Gross Profit | -200.0K |
| Operating Expense | 7,091.0K |
| Operating I/L | -7,291.0K |
| Other Income/Expense | 325.0K |
| Interest Income | 325.0K |
| Pretax | -6,966.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -6,966.0K |
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company specializing in the development of small molecules to address neurodegenerative diseases. Its lead product candidate, ATH-1017, is undergoing Phase 3 and Phase 2 clinical trials for Alzheimer's and Parkinson's diseases, respectively. The company also has preclinical stage product candidates, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions.
